In addition, AZD5991 shows enhanced efficacy against growth of MM and AML subcutaneous tumors when combined with agents that enhance Bim activity and/or Mcl-1-dependency, such as bortezomib or venetoclax. Here, MCL1 is linked to Miyoshi myopathy.